🎤 Upcoming Biotech Conferences
Loading conferences...
Free public preview
Track neurology and CNS catalysts with approval-probability scores and free alerts.
Neurology & CNS Biotech Pipeline: Brain and Nervous System Drugs
Every neurology and CNS program BioRadar tracks across 7 public biotech companies — drug candidates, trial phases and upcoming FDA decisions. Updated automatically.
BioRadar is tracking 62 neurology and CNS drug programs across 7 public companies, with 1 upcoming FDA decision in this area. The most active companies by program count are BIIB, AXSM, BHVN, ACIU, CORT.
62Drug programs
7Companies
15In Phase 3
1Upcoming FDA dates
Upcoming FDA decisions in Neurology & CNS
| Date | Ticker | Drug / Indication | Type | In |
|---|---|---|---|---|
| May 1, 2027 | AXSM | Cataplexy in Narcolepsy | NDA | 281d |
Companies with neurology and CNS programs
Phase 3 neurology & cns programs (15)
| Ticker | Drug | Indication |
|---|---|---|
| AXSM | Meloxicam | Migraine |
| AXSM | Rizatriptan | Migraine |
| AXSM | AXS-07 | Migraine |
| AXSM | AXS-07 (meloxicam-rizatriptan) | Migraine |
| AXSM | AXS-07 (MoSEIC meloxicam and rizatriptan | Migraine |
| AXSM | AXS-05 (dextromethorphan-bupropion) | Agitation in Patients With Dementia of the Alzheim |
| BIIB | Fingolimod | Relapsing Forms of Multiple Sclerosis |
| BIIB | Diroximel Fumarate | Relapsing Forms of Multiple Sclerosis |
| BIIB | Lecanemab SC | Early Alzheimer's Disease |
| BIIB | Lecanemab IV | Early Alzheimer's Disease |
| BIIB | Interferon β-1a | Relapsing-Remitting Multiple Sclerosis |
| BIIB | Lecanemab | Preclinical Alzheimer's Disease |
| BIIB | Tofersen | Amyotrophic Lateral Sclerosis Associated With a SO |
| BIIB | Dimethyl Fumarate | Relapsing Forms of Multiple Sclerosis |
| CMPS | Psilocybin | Treatment Resistant Depression |
Phase 2 neurology & cns programs (22)
| Ticker | Drug | Indication |
|---|---|---|
| ACIU | ACI-7104.056 at Dose C (optional) | Parkinson Disease |
| ACIU | ACI-7104.056 at Dose B (optional) | Parkinson Disease |
| ACIU | ACI-7104.056 at Dose A | Parkinson Disease |
| AXSM | AXS-12 (reboxetine) | Narcolepsy |
| BHVN | BHV-8000 10mg | Parkinson Disease |
| BHVN | BHV-8000 20 mg | Parkinson Disease |
| BHVN | BHV-8000 | Parkinson Disease |
| BHVN | BHV-2100 | Migraine |
| BHVN | BHV-7000 | Focal Epilepsy |
| BIIB | Diranersen | Mild Cognitive Impairment Due to Alzheimer's Disea |
| BIIB | Lecanemab 5.0 mg/kg | Alzheimer's Disease |
| BIIB | Lecanemab 2.5 mg/kg | Alzheimer's Disease |
| BIIB | Lecanemab 10 mg/kg | Alzheimer's Disease |
| BIIB | DRF | Relapsing Forms of Multiple Sclerosis |
| BIIB | BIIB091 | Relapsing Forms of Multiple Sclerosis |
| BIIB | BIIB122 225 mg | Parkinson Disease |
| BIIB | Tyruko Injectable Product | Multiple Sclerosis |
| BIIB | RTA 901 | Diabetic Peripheral Neuropathic Pain |
| BIIB | BIIB122 | Parkinson Disease |
| CORT | Dazucorilant 300 mg | Amyotrophic Lateral Sclerosis |
| CORT | Dazucorilant 150 mg | Amyotrophic Lateral Sclerosis |
| CORT | Dazucorilant | Amyotrophic Lateral Sclerosis |
Phase 1 neurology & cns programs (5)
Track neurology and CNS catalysts before they hit
BioRadar scores every upcoming FDA decision with an AI Probability of Approval, tracks cash runway and dilution risk, and sends free email alerts. Build a neurology and CNS watchlist in minutes.
Start free →
Data: ClinicalTrials.gov, SEC & FDA filings • Informational only, not investment advice. • All biotech stocks A–Z →